Related Experiment Videos
Malignant lymphoma (reticulum cell sarcoma) of bone
Summary
Malignant lymphoma of the bone shows a 50% 5-year survival rate. Radiotherapy is the primary treatment, with chemotherapy beneficial for widespread disease.
Area of Science:
- Oncology
- Hematology
- Skeletal Diseases
Background:
- Malignant lymphoma can affect skeletal sites.
- Histiocytic type lymphoma presents unique challenges in bone.
- Understanding survival and treatment is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the survival rates of patients with skeletal malignant lymphoma.
- To determine the efficacy of different treatment modalities.
- To identify prognostic factors for histiocytic type lymphoma in bone.
Main Methods:
- Retrospective analysis of 24 patients with skeletal lesions.
- Inclusion of both male and female patients.
- Tracking of patient survival and treatment responses.
Main Results:
- A 5-year survival rate of 50% was observed in the cohort.
- Two patients with primary skeletal lesions survived beyond 6.5 and 15.5 years.
- Radiotherapy emerged as the preferred treatment modality.
Conclusions:
- Skeletal malignant lymphoma, histiocytic type, has a significant but manageable survival rate.
- Radiotherapy is the cornerstone of treatment for bone lymphoma.
- Chemotherapy offers a potential benefit for patients with disseminated disease, warranting further investigation.